My Cart:

0 item(s) - $0.00
You have no items in your shopping cart.


Viraday vs Atripla - Your definitive online guide

Viraday vs Atripla

Viraday vs Artipla is such a common topic and searched for phrase, that we have decided to dedicate a continually updated page to this subject.

We have done all the hard work for you and searched respected pharmacies, HIV forums, prescription drug portals and collated all the evidence on this page.

To see our Viraday vs Atripla Side by Side Comparison table please click here 


Drugs used in the treatment of HIV are known as antiretrovirals. There are several on the market, but two which are gaining in popularity are Atripla and Viraday. This page is dedicated to looking at the similarities and differences between them.

What makes them both unique?

It is because their formulations combine three separate drugs in one convenient tablet dosage. They offer maximum effectiveness in delaying the progression of HIV and inhibiting the development of AIDS.

How does Viraday formulation compare with Atripla?

Atripla and Viraday have the same formulations. Each contains three anti-HIV drugs:

- efavirenz (600 mg) -> Sustiva is the brand name for efavirenz
- emtricitabine (200 mg) -> Emtriva is the brand name for emtricitabine
- tenofovir (300 mg) -> Viread is the brand name for tenofovir

If those active ingredients sound familiar it is because Viread and Emtriva and components of HIV PrEP drug Truvada.

This breakthrough combination means the consumer only needs to take 1 tablet per day, instead of 3 separate tablets.

Also the toxicity of this combination drug has been found to be lower than if the drugs are taken individually.

They are both sold in tablet form. There is no difference in the strength or the compounds used. The adult dosage is one tablet daily at bedtime.

The distinctions between Viraday and Atripla are found in the manufacturers, brand name, country of origin and pricing.

Viraday is the generic form of the brand name Atripla. It is manufactured by Cipla of India and available for a far lower price than its brand name alternative.

Viraday-vs-Atripla help

Viraday by Cipla

ATRIPLA combines SUSTIVA(R) (efavirenz), manufactured by Bristol-Myers Squibb, and Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), manufactured by Gilead Sciences.

Viraday vs Atripla images

Atripla tablets by Gilead

The collaboration between Bristol-Myers Squibb and Gilead Sciences is the first time two US pharmaceutical companies have collaborated on HIV drugs.

ATRIPLA was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006. Viraday was launched by Cipla in October 2006.

In the United States, this product is commercialized by Bristol-Myers Squibb and Gilead Sciences through the companies' joint venture agreement.

The FDA also granted approval of an alternate trade dress of ATRIPLA for developing countries.

Cipla is known for providing HIV/AIDS drugs to the majority of African, South Asian, Latin American and many other developing countries.

Cipla has therefore played a key major role in reducing the price of HIV/AIDS drugs in the international market.

What are the color differences of the tablets?

Outside the USA, Atripla is available as a white-colored tablet. Inside the USA it is salmon-colored.

Viraday from Cipla is also salmon-colored.

Is Viraday as effective as Atripla?

There is no difference in the formulations of Atripla and Viraday. However, studies have shown that results vary from one patient to another. This fixed dose three in one HIV treatment under clinical testing has had positive results for inhibiting the HIV virus.

The three anti-HIV drugs each work in different ways to combat the infection in a fixed dose format. Although they do not cure the condition, they do inhibit the growth of the virus and have shown a high likelihood of preventing the development of AIDS in most cases when used in this combination.

Efavirenz is a non-nucleoside Reverse Transcriptase Inhibitor. These compounds bind to a reverse transcriptase protein (enzyme) and disable it. This inhibits the HIV virus replication because it cannot copy itself without the protein.

Emtricitabine is a Nucleoside Reverse Transcriptase Inhibitor. It interjects false building blocks into the DNA that interfere with the replication process of the HIV virus so it cannot make copies of itself. Their incorporation into the DNA of the virus results in a termination of the replication process.

This does not mean that the disease is killed or that it cannot spread to cells which have not yet been infected.

Tenofovir disoproxyl fumarate is a NRTI but works a little differently. It may also be listed distinctively as NRTI because it acts as a competitive inhibitor in a highly similar way to Tenofovir, but it does not require the same chemical compositions to activate.

Results of treatment with antiretrovirals

Test results have been positive in showing an increase in CD4+ cell counts with a decrease in the viral load found in cells.

In layman's terms, this means that low T cell counts are raising and the virus is decreasing in the body. This is good news for HIV infected patients and it shows a degree of effectiveness for slowing HIV for a longer and healthier life than without treatment. The risk of developing life threatening infections as a result of HIV goes down.

Drug Availability 

On May 4, 2017 the Cipla manufacturing company received approval by the US Food and Drug Administration for generic Abacavir and Lamivudine tablets. These are used for treatment of human immunodeficiency virus (HIV) infection and are the generic version of brand drug Epzicom.

This shows that the tide is turning for lowering prices and making Cipla's drugs more available in the USA.

Viraday, the generic form of Atripla is legally available for sale in India and other Asian countries where the US patent protection currently held is not enforced. Any sale in non-exempt countries is considered to be an infringement on the patents held by the manufacturers. This patent is set to expire this year.

If not renewed, sales in all countries will become legal.

While Atripla has a high availability, Viraday has been limited to sales in the countries and territories where the patent is not enforced and this is why the availability has been low throughout the world.

Side Effect Differences

Atripla and Viraday carry the risk of side effects as with any drug or supplement. Not everyone who takes these drugs will experience some or all of the potential side effects as they vary from one person to another. These are the most common side effects reported in Viraday and Atripla.

Central Nervous System issues include: poor concentration, dizziness, sleepiness or trouble falling and staying asleep.

Less commonly dreams may become intense, vivid and seizures or hallucinations may occur. These may go away after two to four weeks, but should always be reported to your health care provider.

Some patients develop a rash in the second week of use. All rashes should be reported to your doctor but they are usually mild to moderate and require no other treatment. If they do become severe or if blisters develop on the skin, swelling, itchy eyes or pain in the muscles or joints occur, seek immediate medical help.

Less Common Side Effects

Lactic Acidosis may occur when levels of lactic acid incease in the blood. The risk increases with people who are overweight.

Symptoms include abdominal pain, nausea, vomiting diarrhea, tiredness, muscle pain, cold sensations in the legs and arms, lightheadedness or dizziness. This is a potentially life threatening situation and should be reported to your doctor right away.

Thinning and weakening of the bones may occur along with an increased risk of fracture from vitamin D loss due to treatment. Vitamin D3 and calcium supplements may be recommended.

Kidney dysfunction may occur with the use of tenofovir. Testing of the blood and urine is recommended for monitoring.

Lipodystrophy syndrome

This is a rare potential side effect of efavirenz. Cholesterol levels in the blood increase and some people experience increases of fatty deposits in certain places and decreases in others which can cause a changing of body shape.


Efavirenz, a component in Atripla may cause thoughts, attempts or completion of suicide. The data gathered shows that the risk of suicidal thoughts or actions increases by double than for those who do not use this medication.

Mental Health Issues

Other less common side effects of using Efavirenz includes feelings of sadness, fearfulness, hopelessness, depression, anger, difficulty in concentration and focus, irritation, upset, extreme tiredness, lack of energy, difficulty falling asleep or staying awake or unexpected changes in mood.

Individuals with mental or emotional disorders should consult with their physician before using these drugs and seek help immediately if they arise.


Tenofovir is a drug found in Atripla and Viraday which has caused some patients to experience swollen pancreatic glands. In addition, enzymes made by the pancreas increased beyond normal in blood level count. This suggests that pancreatic inflammation may occur in some individuals. Pancreatitis symptoms include sweating, anxiety, nausea, vomiting and abdominal pain.

Cardiac symptoms

Efavirenz may cause feelings of faintness, seizures and abnormalities in heart rhythms. If you have a medical history of cardiac problems, consult with your physician before taking any medication containing


Liver toxicity

Tenofovir may cause side effects for people who are co-infected with HIV and Hepatitis B may notice a worsening of the hepatitis if they stop taking the drug. People with this condition are more susceptible to liver toxicity and regular blood testing is recommended to monitor liver health. Increased liver enzymes may also occur, indicating that liver damage has occurred.

Birth Defects

There is a risk of birth defects when Atripla is taken by women who are pregnant or who will become pregnant.

Swollen breasts may occur in men as a rare side effect which are more common if the individual has low testosterone levels or engages in the use of marijuana.

Should I risk using Viraday or Atripla?

This is a personal decision that should be made upon consultation with your physician. If you are taking other medications, you must be aware that there are possible drug interaction consequences when taking Atripla or Viraday.

These include street drugs, over the counter remedies, herbal supplements and prescription drugs. If there is a potential for drug interaction, your physician may weigh the benefits against the drawbacks. Drug interactions may occur with Viraday/Atripla and:

Other anti-HIV drugs; certain antihistamines, anti-migraine drugs, Cisapride, anti-fungal drugs, anti-psychotic drugs, Efavirenz, FTC, tenofovir, Combivir, Kivexa, Trizivir, 3TC, ritonavir, certain antibiotics, St John's work, Ginkgo biloba, rifampin, anti-seizure medications, cholesterol lowering drugs, narcotics, blood pressure drugs and blood thinners.

There is a risk that Atripla and Viraday will decrease the effectiveness of some medications. It may also result in serious, even fatal consequences with some medications. Some classes of drugs may safely be taken with Atripla or Viraday so it is important to check with your physician to discuss any prescription modifications to make you a better candidate for use of this antiretroviral.

Viraday vs Atripla price comparisons

Comparisons made with popular US pharmacies selling Atripla, show that Viraday prices are significantly lower, especially when purchased through World Trust Pharmacy at the cost of $3.49 per tablet with a full month's supply at the cost of $105.

Compared with leading USA pharmacies, Atripla is priced at

$2615.20 from Target CVS;

$2636.12 at Walmart pharmacies

$2737.00 from HealthWarehouse.

The average blue-collar worker cannot afford these monthly costs as they are above what some families earn.

Cipla's Viraday therefore helps make effective HIV treatment affordable to nearly everyone with the generic equivalent of this expensive drug.

Viraday Reviews

Independent online patient reviews show that the results from Cipla Viraday are just as effective as Viraday, but for a fraction of the cost.

We have collated a list of independent patient Viraday reviews from respected online pharmacies and HIV health forums.

Viraday vs Atripla - Side by Side Comparisons table

Active IngredientsSame as Atriplaefavirenz (600 mg), emtricitabine (200 mg), tenofovir (300 mg)
ManufacturerCiplaBristol-Myers Squibb and Gilead Sciences
StrengthSame as Atripla600 mg/200 mg/300 mg
DosingSame as AtriplaOne tablet a day with water on an empty stomach - ideally at bedtime
Launch dateOctober 2006July 2006
Who is it usually prescribed for?Same as AtriplaPeople 12 years or older who have never taken a HIV drug
Can it be used with other drugs?Same as AtriplaCan be used on its own or with other drugs
Our price for 30 tablets$119.70Not available
Typical USA pharmacy priceNot available$2,650
Tablet colorSalmon colorSalmon color in USA - white outside USA
AvailabilityLimited to sales in India and other Asian countriesHigh
EffectivenessSame as AtriplaVaries between patients
Side effectsSame as AtriplaVaries between patients


Although Atripla and Viraday are the same drugs, there is still a misconception about generics and loss of quality. While this may be true for some manufacturers of generics, Cipla Pharmaceuticals has built a solid reputation for delivering high quality medications at affordable prices.

People who have purchased and used Cipla Viraday report a positive experience with clinically proven results of effectivenss at a significant savings in cost.

The USFDA has reviewed and considered the benefits of the use of this drug, manufactured in India and has given it the seal of approval for use in the treatment of HIV.

After weighing the pros and cons and considering what others have to say about this drug, the verdict is in and it is a positive vote of confidence for Cipla Viraday from India.

Viraday USD Price


Pay via eCheck Protection Status Site protected by Industry leader Sucuri

2018 All Rights Reserved.
To satisfy the requirements of Regulation 7 of the UK Medicines / Advertising Regulations 1994, this site is not intended for use by UK residents
Post your comment

World Trust Pharmacy